Harish Ponnuru
Internal Medicine · Overland Park, KSNPI 1144251430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$935
- Merck$728
- Lilly USA, LLC$568
- Novo Nordisk$471
- Novartis$419
- Pfizer$363
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,27599%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $935 |
| Merck | 46 | $728 |
| Lilly USA, LLC | 31 | $568 |
| Novo Nordisk | 27 | $471 |
| Novartis | 28 | $419 |
| Pfizer | 19 | $363 |
| Johnson & Johnson | 18 | $259 |
| AstraZeneca | 11 | $171 |
| Eisai Inc. | 11 | $168 |
| Medtronic | 1 | $133 |
| Arbor Pharmaceuticals, Inc. | 10 | $129 |
| Amgen | 2 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $111 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Idorsia Pharmaceuticals US Inc | 3 | $64 |
| Exact Sciences | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Ironwood Pharmaceuticals, Inc | 4 | $52 |
| Mannkind Corporation | 1 | $43 |
| Bayer | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Boehringer Ingelheim | 2 | $33 |
| GSK | 2 | $31 |
| Boston Scientific | 1 | $27 |
| Amarin Pharma, Inc. | 2 | $25 |
| Gilead | 1 | $22 |
| Cleerly, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Alvogen Inc | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
| Electromed, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,318 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 11 | $46,771 |
| OzempicSemaglutide | 38 | $39,143 |
| EliquisApixaban | 41 | $35,275 |
| MounjaroTirzepatide | 23 | $25,234 |
| CreonLipase/Protease/Amylase | 12 | $13,259 |
| FarxigaDapagliflozin Propanediol | 17 | $9,996 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,165 |
| Testosterone | 32 | $7,205 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,063 |
| LinzessLinaclotide | 11 | $6,068 |
| SynthroidLevothyroxine Sodium | 20 | $1,292 |
| Ipratropium Bromide | 19 | $1,218 |
| Bupropion XlBupropion Hcl | 29 | $1,099 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $1,021 |
| Metoprolol Succinate | 76 | $843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $471 | $39,14338 claims |
| PfizerEliquis | $363 | $35,27541 claims |
| Lilly USA, LLCMounjaro | $568 | $25,23423 claims |
| AbbVieCreon, Linzess, Synthroid | $935 | $20,62043 claims |
| AstraZenecaFarxiga | $171 | $9,99617 claims |
| GSKBreo Ellipta | $31 | $7,06314 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $39443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Overland Park
- Herbert WaxmanOverland Park$82K
- Shadrach SmithOverland Park$27K
- David EdalatiOverland Park$21K
- Jennifer BrownOverland Park$9K
- Ammar KhalifaOverland Park$8K
- Bruce SalvaggioOverland Park$8K
- Vijaya SamuelOverland Park$8K
- Shazia Walijan MunirOverland Park$7K
- Matthew SwanOverland Park$7K
- Victoria WeaverOverland Park$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.